ES2509616T3 - Procedimientos de diagnóstico del síndrome del intestino irritable - Google Patents
Procedimientos de diagnóstico del síndrome del intestino irritable Download PDFInfo
- Publication number
- ES2509616T3 ES2509616T3 ES10792683.4T ES10792683T ES2509616T3 ES 2509616 T3 ES2509616 T3 ES 2509616T3 ES 10792683 T ES10792683 T ES 10792683T ES 2509616 T3 ES2509616 T3 ES 2509616T3
- Authority
- ES
- Spain
- Prior art keywords
- day
- sample
- tryptase
- ibs
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title abstract description 18
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 102000001400 Tryptase Human genes 0.000 abstract 5
- 108060005989 Tryptase Proteins 0.000 abstract 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 15
- 229960002986 dinoprostone Drugs 0.000 description 15
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 208000024330 bloating Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010058672 Negative thoughts Diseases 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 102100030304 Platelet factor 4 Human genes 0.000 description 2
- 238000012896 Statistical algorithm Methods 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 108700028353 OmpC Proteins 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/809—Multifield plates or multicontainer arrays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22052509P | 2009-06-25 | 2009-06-25 | |
| US220525P | 2009-06-25 | ||
| US25209409P | 2009-10-15 | 2009-10-15 | |
| US252094P | 2009-10-15 | ||
| PCT/US2010/039866 WO2010151699A1 (en) | 2009-06-25 | 2010-06-24 | Methods for diagnosing irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2509616T3 true ES2509616T3 (es) | 2014-10-17 |
Family
ID=43386896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10792683.4T Active ES2509616T3 (es) | 2009-06-25 | 2010-06-24 | Procedimientos de diagnóstico del síndrome del intestino irritable |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8114616B2 (enExample) |
| EP (3) | EP3309556B1 (enExample) |
| JP (3) | JP5736370B2 (enExample) |
| AU (3) | AU2010266028B2 (enExample) |
| CA (1) | CA2766157A1 (enExample) |
| ES (1) | ES2509616T3 (enExample) |
| HK (1) | HK1204048A1 (enExample) |
| WO (1) | WO2010151699A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ619527A (en) | 2009-04-14 | 2015-06-26 | Nestec Sa | Inflammatory bowel disease prognostics |
| EP3309556B1 (en) | 2009-06-25 | 2020-04-08 | Prometheus Biosciences, Inc. | Methods for diagnosing irritable bowel syndrome |
| EP3109638A1 (en) * | 2009-08-03 | 2016-12-28 | Yeda Research And Development Co. Ltd. | Urinary biomarkers for cancer diagnosis |
| PH12012500850A1 (en) * | 2009-10-30 | 2013-01-07 | Prometheus Laboratories Inc | Methods for diagnosing irritable bowel syndrome |
| MX362132B (es) | 2011-05-10 | 2019-01-07 | Nestec Sa | Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado. |
| EP2710383B1 (en) * | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| AU2012325798B2 (en) | 2011-10-21 | 2015-11-26 | Société des Produits Nestlé S.A. | Methods for improving inflammatory bowel disease diagnosis |
| CN104379140A (zh) * | 2012-04-23 | 2015-02-25 | 苏坎波公司 | 用于治疗具有腹泻的肠易激综合征的方法 |
| EP2890982B1 (en) | 2012-08-28 | 2020-12-16 | Puget Sound Blood Center | Biochemical markers of red blood cell storage and toxicity |
| EP3660511A1 (en) * | 2013-01-03 | 2020-06-03 | Meso Scale Technologies, LLC | Assay panels |
| KR101494882B1 (ko) * | 2013-02-21 | 2015-02-25 | 한국과학기술연구원 | 급성 심근 경색 진단용 조성물, 그 조성물을 포함하는 급성 심근 경색 진단용 키트 및 급성 심근 경색 진단 방법 |
| BR112015029318A2 (pt) * | 2013-05-24 | 2017-07-25 | Nestec Sa | marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável |
| EP3236850A4 (en) * | 2014-12-23 | 2018-07-18 | Ent. Services Development Corporation LP | Detection of allergen exposure |
| CN116672446A (zh) | 2015-09-17 | 2023-09-01 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| HK1255922A1 (zh) | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
| BR112018012626A2 (pt) | 2015-12-22 | 2018-12-04 | Amgen Inc | ccl20 como um preditor de resposta clínica a antagonistas de il23 |
| CA3135012A1 (en) | 2017-05-31 | 2018-12-06 | Anjali Jain | Methods for assessing mucosal healing in crohn's disease patients |
| CN110785172A (zh) * | 2017-07-21 | 2020-02-11 | 红山生物医药有限公司 | Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途 |
| WO2019111126A1 (en) * | 2017-12-06 | 2019-06-13 | Alma Mater Studiorum - Università di Bologna | Method and kit for diagnosing non celiac gluten sensitivity |
| WO2019195146A1 (en) * | 2018-04-03 | 2019-10-10 | Boston Scientific Scimed, Inc. | Systems and methods for diagnosing and/or monitoring disease |
| US11621077B2 (en) * | 2019-09-30 | 2023-04-04 | Kpn Innovations, Llc. | Methods and systems for using artificial intelligence to select a compatible element |
| US20230074127A1 (en) * | 2020-01-27 | 2023-03-09 | Immundiagnostik Ag | Test and in vitro diagnosis of irritable bowel syndrome |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4277250A (en) | 1979-12-10 | 1981-07-07 | Baylor College Of Medicine | Methods for detecting and quantifying occult blood |
| JPH0684970B2 (ja) | 1987-03-31 | 1994-10-26 | 株式会社京都医科学研究所 | 糞便中の潜血検出方法 |
| US5081040A (en) | 1987-06-29 | 1992-01-14 | Helena Laboratories Corporation | Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes |
| JPH0736013B2 (ja) | 1991-04-27 | 1995-04-19 | 一男 田畑 | 潜血検出用試薬 |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| DE69424700T2 (de) | 1993-03-10 | 2000-11-09 | Cedars-Sinai Medical Center, Los Angeles | Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis |
| US5395932A (en) * | 1993-04-30 | 1995-03-07 | G. D. Searle & Co. | 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US6867197B1 (en) * | 1995-03-30 | 2005-03-15 | Mitokor | Method of targeting conjugate molecules to mitochondria |
| US5594116A (en) * | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
| US6074835A (en) | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| JP2000065820A (ja) * | 1998-08-19 | 2000-03-03 | Allergen Free Technology Kenkyusho:Kk | タンパク質抽出用水溶液及び抽出方法並びにアレルゲン分析方法 |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| FR2802536B1 (fr) | 1999-11-23 | 2003-06-13 | Chru Lille | Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections |
| FR2806739B1 (fr) | 2000-03-27 | 2005-02-18 | Fond Jean Dausset Ceph | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| US6797461B2 (en) * | 2000-10-27 | 2004-09-28 | Promega Corporation | Tryptase substrates and assay for tryptase activity using same |
| ES2325059T3 (es) | 2000-11-14 | 2009-08-25 | Techlab, Inc. | Metodo para diferenciar el sindrome del intestino irritable de la enfermedad inflamatoria intestinal (ibd) y para seguir personas con ibd usando la lactoferrina endogena total como marcador. |
| US20050043304A1 (en) * | 2001-08-01 | 2005-02-24 | Yutaka Kato | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same |
| CA2476755C (en) | 2001-12-17 | 2014-08-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| EP2364718B1 (en) | 2002-02-14 | 2016-07-06 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| US20030229030A1 (en) | 2002-06-11 | 2003-12-11 | Theoharides Theoharis C. | Method of treating interleukin-6-mediated inflammatory diseases |
| ATE395596T1 (de) | 2002-10-25 | 2008-05-15 | Techlab Inc | Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon |
| ATE491953T1 (de) | 2003-09-15 | 2011-01-15 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| WO2005041896A2 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| WO2006068770A1 (en) | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| AT501347B1 (de) | 2005-02-09 | 2008-07-15 | Biomay Prod & Handel | Verfahren und set zur evaluierung der allergensensibilität eines individuums |
| AU2006330562B2 (en) | 2005-12-22 | 2013-05-02 | Baxter Healthcare S.A. | Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products |
| JP2007186457A (ja) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | トリプターゼ活性阻害剤およびその利用 |
| EP2924440A3 (en) * | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| DK2722052T3 (en) | 2006-07-26 | 2019-04-29 | Biomarck Pharmaceuticals Ltd | Methods for attenuating the release of inflammatory mediators and peptides useful therein |
| US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2205243A4 (en) * | 2007-09-28 | 2012-06-13 | Brigham & Womens Hospital | MAST CELL STABILIZERS FOR THE TREATMENT OF ADIPOSITAS |
| WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
| EP3309556B1 (en) * | 2009-06-25 | 2020-04-08 | Prometheus Biosciences, Inc. | Methods for diagnosing irritable bowel syndrome |
-
2010
- 2010-06-24 EP EP17162202.0A patent/EP3309556B1/en active Active
- 2010-06-24 WO PCT/US2010/039866 patent/WO2010151699A1/en not_active Ceased
- 2010-06-24 EP EP10792683.4A patent/EP2445517B1/en active Active
- 2010-06-24 ES ES10792683.4T patent/ES2509616T3/es active Active
- 2010-06-24 CA CA2766157A patent/CA2766157A1/en not_active Abandoned
- 2010-06-24 JP JP2012517742A patent/JP5736370B2/ja not_active Expired - Fee Related
- 2010-06-24 EP EP14170774.5A patent/EP2778685B1/en active Active
- 2010-06-24 AU AU2010266028A patent/AU2010266028B2/en not_active Ceased
- 2010-08-24 US US12/862,707 patent/US8114616B2/en active Active
-
2012
- 2012-01-17 US US13/352,225 patent/US8709733B2/en active Active
-
2014
- 2014-03-21 US US14/222,531 patent/US9482672B2/en active Active
-
2015
- 2015-03-16 HK HK15102656.4A patent/HK1204048A1/en unknown
- 2015-04-20 JP JP2015086029A patent/JP6087974B2/ja not_active Expired - Fee Related
- 2015-07-23 AU AU2015205899A patent/AU2015205899B2/en not_active Ceased
-
2017
- 2017-02-02 JP JP2017017718A patent/JP6634544B2/ja not_active Expired - Fee Related
- 2017-08-11 AU AU2017213566A patent/AU2017213566B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US8114616B2 (en) | 2012-02-14 |
| US20110159521A1 (en) | 2011-06-30 |
| US20120244558A1 (en) | 2012-09-27 |
| EP2445517A4 (en) | 2013-02-27 |
| AU2015205899A1 (en) | 2015-08-20 |
| JP2017129587A (ja) | 2017-07-27 |
| EP2778685B1 (en) | 2017-04-26 |
| JP2015155918A (ja) | 2015-08-27 |
| US9482672B2 (en) | 2016-11-01 |
| CA2766157A1 (en) | 2010-12-29 |
| US20140199709A1 (en) | 2014-07-17 |
| EP3309556A1 (en) | 2018-04-18 |
| AU2015205899B2 (en) | 2017-05-11 |
| EP2445517B1 (en) | 2014-07-30 |
| WO2010151699A1 (en) | 2010-12-29 |
| AU2017213566B2 (en) | 2019-05-02 |
| HK1204048A1 (en) | 2015-11-06 |
| JP6087974B2 (ja) | 2017-03-01 |
| EP3309556B1 (en) | 2020-04-08 |
| AU2017213566A1 (en) | 2017-08-31 |
| JP6634544B2 (ja) | 2020-01-22 |
| AU2010266028B2 (en) | 2015-04-30 |
| AU2010266028A1 (en) | 2012-01-19 |
| JP5736370B2 (ja) | 2015-06-17 |
| US8709733B2 (en) | 2014-04-29 |
| EP2778685A1 (en) | 2014-09-17 |
| JP2012531593A (ja) | 2012-12-10 |
| EP2445517A1 (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2509616T3 (es) | Procedimientos de diagnóstico del síndrome del intestino irritable | |
| Mandell et al. | The prevalence and correlates of abuse among children with autism served in comprehensive community-based mental health settings | |
| Matijasevich et al. | Validation of the Edinburgh Postnatal Depression Scale (EPDS) for screening of major depressive episode among adults from the general population | |
| Guerchet et al. | Cognitive impairment and dementia in elderly people living in rural Benin, west Africa | |
| Merikangas et al. | The structured diagnostic interview for sleep patterns and disorders: rationale and initial evaluation | |
| Usai et al. | Effect of gluten-free diet and co-morbidity of irritable bowel syndrome-type symptoms on health-related quality of life in adult coeliac patients | |
| Çolak Sivri et al. | Cytokine, chemokine and BDNF levels in medication-free pediatric patients with obsessive–compulsive disorder | |
| Manan et al. | The influences of parenting stress, children behavioral problems and children quality of life on depression symptoms among parents of children with autism: Preliminary findings | |
| Zafar et al. | Pattern and prevalence of menstrual disorders in adolescents | |
| Benitez et al. | Self-reported cognition and marijuana use in older adults: Results from the national epidemiologic survey on alcohol and related conditions-III | |
| Zappitelli et al. | Temperament and character traits in children and adolescents with major depressive disorder: a case–control study | |
| Loo et al. | Cancer awareness of a sample of Malaysian undergraduate students | |
| Tarricone et al. | Psychotic symptoms and general health in a socially disadvantaged migrant community in Bologna | |
| Oh et al. | Development and clinical validity of a mild vascular cognitive impairment assessment tool for Korean stroke patients | |
| Shanahan et al. | Developmental timing of suicide attempts and cardiovascular risk during young adulthood. | |
| Leiva et al. | Relationship between adverse childhood experiences and mental health: Implications for a nationwide school mental health program | |
| Obare | Nonresponse in repeat population-based voluntary counseling and testing for HIV in rural Malawi | |
| Madebe et al. | Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern, Tanzania | |
| Liao et al. | Prevalence of lower urinary tract symptoms among female elementary school teachers in Taipei | |
| Crafa | Migration and autism diagnosis | |
| Coid et al. | M132. Urbanicity and psychosis in a chinese undergraduate population: preliminary findings | |
| Zahari et al. | Reliability and Validity of Malay Version of Revised Oswestry Low Back Pain Disability Questionnaire | |
| Hazır et al. | Factors affecting the postoperative quality of life and psychological well-being in pediatric urology patients | |
| Gouda Ahmed et al. | Effect of Instructional Guidelines on Knowledge and Self-care Practices of Pregnant Women with Urinary Tract Infections | |
| Wang et al. | Latent profile analysis of demoralization syndrome in elderly stroke patients with disability |